Whole-blood RNA transcript-based models can predict clinical response in two large independent clinical studies of patients with advanced melanoma treated with the checkpoint inhibitor, tremelimumab

BACKGROUND: Tremelimumab is an antibody that blocks CTLA-4 and demonstrates clinical efficacy in a subset of advanced melanoma patients. An unmet clinical need exists for blood-based response-predictive gene signatures to facilitate clinically effective and cost-efficient use of such immunotherapeut...

Descripción completa

Detalles Bibliográficos
Autores principales: Friedlander, Philip, Wassmann, Karl, Christenfeld, Alan M., Fisher, David, Kyi, Chrisann, Kirkwood, John M., Bhardwaj, Nina, Oh, William K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5557000/
https://www.ncbi.nlm.nih.gov/pubmed/28807052
http://dx.doi.org/10.1186/s40425-017-0272-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5557000/
https://www.ncbi.nlm.nih.gov/pubmed/28807052
http://dx.doi.org/10.1186/s40425-017-0272-z

Ejemplares similares